Ruxolitinib - Incyte Corporation/Novartis

Alternative Names: INC-424; INCB 018424 phosphate; INCB-018424; INCB-18424; Jakafi; Jakavi; Opzelura; RUX; ruxolitinib phosphate

Latest Information Update: 21 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Incyte Corporation
Developer Baylor Breast Care Center; CMS Medical; Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Lymphoma Academic Research Organisation; National Cancer Institute (USA); Novartis; RWTH Aachen University; University Health Network of Toronto; University of Cologne; University of Rochester; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
Class 2 ring heterocyclic compounds; Anti-inflammatories; Antianaemics; Antibronchitics; Antihaemorrhagics; Antineoplastics; Antipsoriatics; Antirheumatics; Antivirals; Cyclopentanes; Nitriles; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Myelofibrosis; Pancreatic cancer; Polycythaemia vera; Essential thrombocythaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Graft-versus-host disease
New Molecular Entity Yes

Marketed Atopic dermatitis; Graft-versus-host disease; Myelofibrosis; Polycythaemia vera; Vitiligo
Phase III Cytokine release syndrome; Essential thrombocythaemia; Prurigo nodularis; SARS-CoV-2 acute respiratory disease
Phase II/III COVID-19 pneumonia
Phase II Acute myeloid leukaemia; Alopecia areata; Breast cancer; Breast disorders; Bronchiolitis obliterans; Cachexia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Discoid lupus erythematosus; Haematological malignancies; Head and neck cancer; Hidradenitis suppurativa; HIV infections; Hodgkin's disease; Lichen planus; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Thalassaemia; Vulvar lichen sclerosus
Phase I/II Anaemia; HER2 positive breast cancer; Multiple myeloma
Phase I Adenocarcinoma
No development reported Psoriasis
Discontinued Colorectal cancer; HER2 negative breast cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Rheumatoid arthritis

15 Aug 2024 Incyte Corporation plans a phase I bioequivalence trial (In volunteers) in September 2024 (PO, Tablet) (NCT06555081)
12 Aug 2024 Incyte Corporation plans a phase III trial for Vitiligo (In children) (Topical), in November 2024 (NCT06548360)
30 Jul 2024 Incyte plans a phase III trial for Hidradenitis suppurativa (Topical, Cream) in 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com